Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953867 | 1.00 | CA1 (0.52) | CA1CA2AKR1C3AKR1C2NQO1 | |
| SCHEMBL4084548 | 0.86 | CA1 (0.48) | CA1CA2CA12CA4CA6 | |
| SCHEMBL29954116 | 0.83 | NR5A1 (0.49) | CA1CA2CA12CA4CA6 | |
| SCHEMBL9072 | 0.82 | NQO1 (0.64) | CA1CA2NQO1ENPP2LTA4H | |
| SCHEMBL4748948 | 0.82 | NR5A1 (0.51) | CA1CA2LTA4HTSHRLPL | |
| SCHEMBL29629327 | 0.82 | NQO1 (0.68) | CA1AKR1C3AKR1C2NQO1CA12 | |
| SCHEMBL3825385 | 0.82 | NQO1 (0.68) | CA1AKR1C3AKR1C2NQO1CA12 | |
| SCHEMBL8505542 | 0.82 | NR5A1 (0.51) | CA1CA2LTA4HTSHRLPL | |
| SCHEMBL4748959 | 0.82 | NR5A1 (0.51) | CA1CA2LTA4HTSHRLPL | |
| SCHEMBL2560860 | 0.81 | CA1 (0.47) | CA1CA2AKR1C3AKR1C2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-9980668-B2 | Photoluminescent nanostructure-based sensors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-29 | — | — | US | claimed |
| EP-2739977-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | Massachusetts Institute of Technology (US) | 2014-06-11 | — | — | EP | claimed |
| WO-2013019722-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-02-07 | — | — | WO | claimed |
| US-20130035567-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | NATIONAL SCIENCE FOUNDATION | 2013-02-07 | — | — | US | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-12402638-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12232516-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-12193465-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4447963-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | disclosed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11737481-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-112470045-B | Optical filter and display device | 住友化学株式会社 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023111990-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-107434973-B | Liquid crystal compound and composition and application thereof | 江苏和成显示科技有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | disclosed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| CN-112469695-A | Compound and method for producing same | 住友化学株式会社 | 2021-03-09 | — | — | CN | disclosed |
| CN-112470045-A | Optical filter and display device | 住友化学株式会社 | 2021-03-09 | — | — | CN | disclosed |
| EP-3786156-A1 | 10H-PHENOTHIAZINE FERROPTOSIS INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Chengdu Henghao Investment Co. Limited (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20210040079-A1 | 10H-phenothiazine ferroptosis inhibitor as well as the preparative method and the use thereof | Chengdu Henghao Investment Co. Limited (CN) | 2021-02-11 | — | — | US | disclosed |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| EP-3319964-B1 | DITHIO-ALKYL-PYRROLO-PYRROLES AND USE THEREOF AS DYES | MERCK PATENT GMBH (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-20200223803-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2020-07-16 | — | — | US | disclosed |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2020-04-28 | — | — | US | disclosed |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2020022135-A1 | OPTICAL FILTER AND DISPLAY DEVICE | 住友化学株式会社 | 2020-01-30 | — | — | WO | disclosed |
| WO-2020022134-A1 | COMPOUND AND METHOD FOR PRODUCING SAME | 住友化学株式会社 | 2020-01-30 | — | — | WO | disclosed |
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | University of Washington Through its Center for Co (US) | 2020-01-28 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | disclosed |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | disclosed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | disclosed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | disclosed |
| EP-2786985-B1 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| EP-2719384-B1 | Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9980668-B2 | Photoluminescent nanostructure-based sensors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-29 | — | — | US | disclosed |
| US-9956214-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2018-01-04 | — | — | US | disclosed |
| EP-3250290-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | University of Washington (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9765037-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765037-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-9737506-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2999696-B1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2496567-B1 | NOVEL BENZOPYRAN KINASE MODULATORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-07-12 | — | — | EP | disclosed |
| US-9701626-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170056389-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-03-02 | — | — | US | disclosed |
| WO-2017008880-A1 | DITHIO-ALKYL-PYRROLO-PYRROLES AND USE THEREOF AS DYES | MERCK PATENT GMBH (DE) | 2017-01-19 | — | — | WO | disclosed |
| US-9518026-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| EP-2528919-B1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIV WASHINGTON (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9421209-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-23 | — | — | US | disclosed |
| WO-2016123151-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123152-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123152-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123151-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160090362-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-31 | — | — | US | disclosed |
| EP-2999696-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | University Of Washington Through Its Center For Commercialization (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2016-01-14 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9205074-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9169201-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2015-05-28 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014189947-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-11-27 | — | — | WO | disclosed |
| US-8877798-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2739977-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | Massachusetts Institute of Technology (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2129654-B1 | ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8710236-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2719384-A1 | Novel 1 -naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neurophychiatric disorders | Euthymic Bioscience, Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130345439-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2013-12-26 | — | — | US | disclosed |
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | disclosed |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2013019722-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20130035567-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | NATIONAL SCIENCE FOUNDATION | 2013-02-07 | — | — | US | disclosed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-8349814-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349814-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8329675-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329675-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2528919-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | University of Washington (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| EP-2404607-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011094628-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIVERSITY OF WASHINGTON (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
| US-7776922-B2 | Substituted [(phenylethanoyl)amino]benzamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | disclosed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-7449484-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080171786-A1 | e.g. 2-(1-Benzothien-2-yl)-5-[(2-phenylbutanoyl)amino]benzamide; interleukin-8 receptor antagonist; antiinflammatory agent, cardiovascular diseases; arteriosclerosis, coronary heart disease, dyslipidemias, myocardial infarction, stroke, restenosis, reperfusion injury, thrombosis, ischemia | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1915146-A2 | NOVEL 1-ARYL-3-AZABICYCLOÝ3.1.0¨HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS | DOV Pharmaceutical, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1814872-A1 | SUBSTITUTED [(PHENYLETHANOYL)AMINO] BENZAMIDES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AND CARDIO-VASCULAR DISEASES | Bayer HealthCare AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1343779-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| WO-2007016155-A2 | NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20060166988-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006053748-A1 | SUBSTITUTED [(PHENYLETHANOYL)AMINO] BENZAMIDES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AND CARDIO-VASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2006-05-26 | — | — | WO | disclosed |
| WO-2005014525-A2 | BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY | MITSUBISHI PHARMA CORPORATION (JP) | 2005-02-17 | — | — | WO | disclosed |
| US-20040053943-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1343779-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1343779-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002039954-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002039954-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040079-A1 | 10H-phenothiazine ferroptosis inhibitor as well as the preparative method and the use thereof | AIFM2, FECH, GPX4 | CA1 809/4885CA2 2427/4885AKR1C3 3595/4885 |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | CA1 4598/4885CA2 3153/4885AKR1C3 3535/4885 |
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | CA1 2479/4885CA2 541/4885AKR1C3 556/4885 |
| US-20080171786-A1 | e.g. 2-(1-Benzothien-2-yl)-5-[(2-phenylbutanoyl)amino]benzamide; interleukin-8 receptor antagonist; antiinflammatory agent, cardiovascular diseases; arteriosclerosis, coronary heart disease, dyslipidemias, myocardial infarction, stroke, restenosis, reperfusion injury, thrombosis, ischemia | CXCL8, CASP8, TLR8 | CA1 4458/4885CA2 3223/4885AKR1C3 2698/4885 |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | CA1 1204/4885CA2 210/4885AKR1C3 3498/4885 |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CA1 4615/4885CA2 3756/4885AKR1C3 3627/4885 |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | PNCK, TXK, CAMKK1 | CA1 897/4885CA2 191/4885AKR1C3 3104/4885 |
| US-20130345439-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885AKR1C3 330/4885 |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, TXK, CAMKK1 | CA1 897/4885CA2 191/4885AKR1C3 3104/4885 |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1D, HTR1B | CA1 3381/4885CA2 4858/4885AKR1C3 1271/4885 |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | CA1 1204/4885CA2 210/4885AKR1C3 3498/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CA1 4615/4885CA2 3756/4885AKR1C3 3627/4885 |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | CHEK2, CHEK1, DCK | CA1 3797/4885CA2 1837/4885AKR1C3 4102/4885 |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | CA1 2436/4885CA2 514/4885AKR1C3 538/4885 |
| US-20040053943-A1 | Novel compounds | TIE1, TEK, VEGFA | CA1 4750/4885CA2 3227/4885AKR1C3 1036/4885 |
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | CA1 1204/4885CA2 210/4885AKR1C3 3498/4885 |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 822/4885CA2 1487/4885AKR1C3 264/4885 |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | CHEK2, CHEK1, DCK | CA1 3797/4885CA2 1837/4885AKR1C3 4102/4885 |
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | CA1 1350/4885CA2 118/4885AKR1C3 974/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-10239829-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | CA1 2324/4885CA2 416/4885AKR1C3 588/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 822/4885CA2 1487/4885AKR1C3 264/4885 |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | CA1 1204/4885CA2 210/4885AKR1C3 3498/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | CA1 4827/4885CA2 3510/4885AKR1C3 3810/4885 |
| US-20170056389-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | PCK1, DCK, CILK1 | CA1 1809/4885CA2 999/4885AKR1C3 4242/4885 |
| US-20060166988-A1 | Novel compounds | TIE1, TEK, VEGFA | CA1 4750/4885CA2 3227/4885AKR1C3 1036/4885 |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | CA1 821/4885CA2 1188/4885AKR1C3 305/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CA1 4615/4885CA2 3756/4885AKR1C3 3627/4885 |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | CA1 2479/4885CA2 541/4885AKR1C3 556/4885 |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, CAMKK1, CILK1 | CA1 928/4885CA2 204/4885AKR1C3 3128/4885 |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885AKR1C3 330/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CA1 4615/4885CA2 3756/4885AKR1C3 3627/4885 |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885AKR1C3 330/4885 |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | GLP1R, GCGR, GPR119 | CA1 2479/4885CA2 541/4885AKR1C3 556/4885 |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CA1 1918/4885CA2 2856/4885AKR1C3 882/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | CA1 2479/4885CA2 541/4885AKR1C3 556/4885 |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885AKR1C3 330/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CA1 4615/4885CA2 3756/4885AKR1C3 3627/4885 |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CA1 3475/4885CA2 4866/4885AKR1C3 1613/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | CA1 2285/4885CA2 426/4885AKR1C3 565/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | CA1 4543/4885CA2 3288/4885AKR1C3 1355/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CA1 4615/4885CA2 3756/4885AKR1C3 3627/4885 |
| US-20160090362-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | PCK1, DCK, CILK1 | CA1 1809/4885CA2 999/4885AKR1C3 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.